Cytodyn OTC Stock Analysis

CYDY
 Stock
  

USD 0.35  0.01  2.78%   

The current slide in stock price could raise concerns from investors as the firm is trading at a share price of 0.35 on 917,700 in volume. The company management teams have failed to build on market volatilities in November. However, diversifying your overall positions with Cytodyn may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.6. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cytodyn partners.
Continue to Trending Equities.
  
The Cytodyn otc stock analysis report makes it easy to digest most publicly released information about Cytodyn and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cytodyn OTC Stock analysis module also helps to analyze the Cytodyn price relationship with some important fundamental indicators such as market cap and management efficiency.

Cytodyn OTC Stock Analysis Notes

The company recorded a loss per share of 0.23. Cytodyn had not issued any dividends in recent years. CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.The quote for Cytodyn is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Cytodyn please contact Nader Pourhassan at 360 980 8524 or go to https://www.cytodyn.com.

Cytodyn Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more otcs at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cytodyn's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytodyn or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cytodyn generated a negative expected return over the last 90 days
Cytodyn has high historical volatility and very poor performance
Cytodyn has some characteristics of a very speculative penny stock
The company currently holds 37.35 M in liabilities. Cytodyn has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cytodyn until it has trouble settling it off, either with new capital or with free cash flow. So, Cytodyn's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytodyn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytodyn to invest in growth at high rates of return. When we think about Cytodyn's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 266 K. Net Loss for the year was (210.82 M) with loss before overhead, payroll, taxes, and interest of (73.28 M).
Cytodyn currently holds about 4.68 M in cash with (77.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.

Cytodyn Upcoming and Recent Events

Earnings reports are used by Cytodyn to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytodyn previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report13th of August 2021
Next Financial Report8th of October 2021
Next Fiscal Quarter End31st of May 2021
Next Fiscal Year End13th of August 2021
Last Quarter Report28th of February 2021
Last Financial Announcement31st of May 2020

Cytodyn Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 280.5 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytodyn's market, we take the total number of its shares issued and multiply it by Cytodyn's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (1.2511) % which means that it has lost $1.2511 on every $100 spent on asset. This is way below average. Cytodyn management efficiency ratios could be used to measure how well cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 4th of December, Cytodyn shows the risk adjusted performance of (0.08), and Mean Deviation of 3.97. Cytodyn technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Cytodyn, which can be compared to its rivals. Please confirm Cytodyn variance and potential upside to decide if Cytodyn is priced correctly, providing market reflects its regular price of 0.35 per share. As Cytodyn appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Cytodyn Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Cytodyn price series with the more recent values given greater weights.
.

Cytodyn Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytodyn insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytodyn's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytodyn insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Migliarese Antonio over two months ago via Macroaxis 
Acquisition by Migliarese Antonio of 10292 shares of Cytodyn subject to Rule 16b-3
Arman Arvin Cyrus over two months ago via Macroaxis 
Acquisition by Arman Arvin Cyrus of 1575557 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over two months ago via Macroaxis 
Acquisition by Migliarese Antonio of 7086 shares of Cytodyn subject to Rule 16b-3
Brunke Karen J over two months ago via Macroaxis 
Acquisition by Brunke Karen J of 247111 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 8313 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 5208 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 5614 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 9824 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 10292 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 10807 shares of Cytodyn subject to Rule 16b-3
Migliarese Antonio over three months ago via Macroaxis 
Acquisition by Migliarese Antonio of 13509 shares of Cytodyn subject to Rule 16b-3
Gardiner Gordon A over a year ago via Macroaxis 
Acquisition by Gardiner Gordon A of 93750 shares of Cytodyn subject to Rule 16b-3

Cytodyn Technical and Predictive Indicators

Cytodyn Forecast Models

Cytodyn time-series forecasting models is one of many Cytodyn's otc stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cytodyn's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Cytodyn OTC Stock Analysis

OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Cytodyn prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cytodyn shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual OTC such as Cytodyn. By using and applying Cytodyn OTC Stock analysis, traders can create a robust methodology for identifying Cytodyn entry and exit points for their positions.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Cytodyn to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run ETF Directory Now

   

ETF Directory

Find actively traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module
Continue to Trending Equities. Note that the Cytodyn information on this page should be used as a complementary analysis to other Cytodyn's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for Cytodyn OTC Stock analysis

When running Cytodyn price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Please note, there is a significant difference between Cytodyn's value and its price as these two are different measures arrived at by different means. Investors typically determine Cytodyn value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytodyn's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.